KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Net Income (2016 - 2025)

Historic Net Income for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $5.4 million.

  • Pacira BioSciences' Net Income rose 10378.63% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 12362.81%. This contributed to the annual value of -$99.6 million for FY2024, which is 33730.19% down from last year.
  • Per Pacira BioSciences' latest filing, its Net Income stood at $5.4 million for Q3 2025, which was up 10378.63% from -$4.8 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Net Income high stood at $25.8 million for Q2 2023, and its period low was -$143.5 million during Q3 2024.
  • Over the past 5 years, Pacira BioSciences' median Net Income value was $9.0 million (recorded in 2024), while the average stood at $296631.6.
  • Per our database at Business Quant, Pacira BioSciences' Net Income surged by 166681.1% in 2023 and then plummeted by 142129.31% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' Net Income stood at -$5.1 million in 2021, then tumbled by 96.92% to -$10.1 million in 2022, then skyrocketed by 346.19% to $24.9 million in 2023, then crashed by 35.5% to $16.0 million in 2024, then plummeted by 66.14% to $5.4 million in 2025.
  • Its Net Income was $5.4 million in Q3 2025, compared to -$4.8 million in Q2 2025 and $4.8 million in Q1 2025.